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A short review is given of antimalarial drugs currently in
use.
S. Air. Med. l., 48, 1263 (1974).
CLASSIFICATION
The chemotherapy of malaria may be conveniently classi-
fied as (i) casual prophylaxis; (ii) suppressive treatment;
(iii) clinical cure; (iv) radical cure; and (v) gametocytocidal
drugs.
Causal Prophylaxis
Causal prophylaxis prevents demonstrable infection by
exerting a lethal effect on the parasites during the pre-
erythrocytic stage. Primaquine i~ the most effective agent
against the primary tissue stage - but impracticable due
to side-effects. Pyrimethamine and chloroguanide ar~ active
against this stage of P. !alciparum but weak .against P.
vivax infections.
Suppressive Treatment
Suppressive treatment causes the inhibition of the
erythrocytic stage of development so that the individual
is kept free of clinical manifestations. Chloroquine (pre-
ferably with pyrimethamine) and, rarely, chloroguanide
are used (a chloroquine-pyrimethamine combination is
preferred), and in multiresistant strains, pyrimethamine
with dapsone, and pyrimethamine (or trimethoprim) with
a long-acting sulphonamide. Suppressive cure occurs
eventually in P. falciparum malaria, and sometimes with
P. vivax infections, but the latter usually recurs.
Clinical Cure
The clinical cure is the termination of the clinical
attack by interruption of erythrocytic schizogony. Drugs
of choice are the 4-aminoquinolines, and in multiresistant
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forms, qUlrune or a combination of a diaminopyrimidine
with a long-acting sulphonamide.
Radical Cure
A radical cure implies elimination of the secondary
tissue phase, usually of P. vivax malaria, as well as the
erythrocytic phase. The 8-aminoquinolines are the only
really effective drugs against the secondary tissue schizonts,
although the diaminopyrimidines may have some effect.
Gametocytocidal (or Static) Drugs
These drugs prevent transmission via the mosquito by
an effect on gametocytes, either in the human host or by
preventing development of sporozoites in the mosquito
(pyrimethamine and chloroguanide affect both P. vivax
and P. falciparum). All the remaining antimalarials are
active against P. vivax gametocytes in the blood, but P.
falciparum gametocytes are sensitive only to primaquin.
MECHANISM OF ACTION OF ANTI-
MALARIAL AGENTS
The 'older' agents with a rapid schizontocidal action are
the 4-aminoquinolines, quinine and acridines. They inter-
act with, and alter, DNA. The reasons for their selective
toxicity are accumulation in the parasitised cell due to an
affinity for nucleates and their partition profiles, which
determine passive diffusion into the cell.
The dihydrofolate reductase inhibitors (chloroguanide,
diaminopyrimidines) prevent folinic acid formation.
Trimethoprim's action (in combination with a sulphona-
mide) is more rapid and it is less vulnerable to induction
of resistance than pyrimethamine, probably because the
latter not only attaches to the reductase, but also pro-
tects it against the proteolytic enzyme, pronase. The
selective toxicity of these agents is due to differing sensi-
tivities of the various dihydrcfolate reductases to inhibi-
tion. The sulphonamides and suiphones act --in sequence
with the abovementioned drugs by competing with PABA
in the synthesis of folic acid.
Both G-6-PD-deficient erythrocytes and the secondary
tissue schizonts appear to have a similar enzyme defect
involving the pentose-phosphate pathway, making them
susceptible to oxidation damage by the quinoline-quinone
metabolites of the 8-aminoquinolines (primaquin).
(NADPH is not regenerated rapidly enough to reduce the
oxidised glutathione to reduced glutathione which protects
SH-dependent enzymes from oxidation.)





This drug is well absorbed after oral administration
(decreased by diarrhoea). Tissue concentrations are higher
than those in plasma (leucocytes have 200 times the plasma
concentration). Parasitised red cells contain a high con-
centration. In 'resistance' this does not occur. Brain levels
are 10 - 30 times those in plasma. In spite of tissue affinity,
a steady state is achieved after 10 daily 31O-mg (base) doses
(but a loading 'dose' is necessary in clinical attacks).
Plasma levels maintain a plateau of ± 125 }Jog/litre only
after 5 weeks of weekly doses. Plasma half-life varies, in-
creasing as concentration falls. A dose of 310 mg (base)
weekly results in peak levels of 150 - 250 p.g/litre with a
half-life of 3-5 days, falling to 20 - 40 p.g/litre imme-
diately before the succeeding dose. Complete suppression
may, according to some authors, be possible at plasma
concentrations of 8 - 10 p.g/ litre. Urinary excretion is slow,
but can be increased by an acid urine, since 70% is ex-
creted unchanged. Other 4-aminoquinolines raise the
plasma level of chloroquine.
Its efficacy as a causal prophylactic is nil. It is effective
for suppression and against clinical attack, but it is in-
effective against sexual forms of P. falciparum.
Quinacrine
Quinacrine is similar in many respects to cWoroquine,
but it has a very high affinity for tissues, and therefore a
loading dose 2 weeks before entering a malarious area is
necessary. To maintain adequate blood levels for suppres-
sion, daily doses are given.
Quinine
A peak plasma level is reached after about 3 hours
and falls to zero after 24 hours. No cumulation occurs.
Only 5% is excreted unaltered. A daily suppressive dose
of I g results in plasma levels of 7 mgjlitre, but to main-
tain a plateau, 6-hourly administration is called for.
Its efficacy is the same as cWoroquine, but it is used
mostly in acute attacks caused by cWoroquine-resistant
P. falciparum strains.
Chloroguanide and the Diaminopyrimidines
They are slowly but adequately absorbed. Chloroguanide
is rapidly excreted (within 24 hours). No cumulative effect
occurs and daily dosage is necessary. Erythrocytes con-
centrate the drug. Sixty per cent is excreted as the paTent
qrug.
It has a weak action on exo-erythrocytic schizonts. It is
effective as a gametocytocide (P. vivax) and sporontocide
(P. vivax and P. falciparum), and .also. for suppression,
although resistance occurs readily. The action is too slow
for use in clinical attacks.
Pyrimethamine
Pyrimethamine differs from chloroguanide in that it is
excreted much more slowly - a single 25-mg dose can
confer protection (suppression) for up to 2 weeks. Signi-
ficant plasma levels are still found after one week (±200
fLg/litre). Maximal plasma levels are attained within 4
hours. The efficacy is similar to that of chloroguanide, but
the tendency to induce resistance is less. The drug is
excreted in the milk of nursing mothers.
Trimethoprim
Trimethoprim is well absorbed, peak plasma levels
occurring in 2 - 4 hours, and some drug persists for 24
hours. The half-life is about 16 hours. Tissue concentra-
tions are higher than those in plasma. It IS used in com-
bination with a sulphonamide against the acute attack
where multiresistant strains are involved. Induction of
resistance is low thus far.
Long-Acting Sulphonamides
Two preparations have had limited trials in combination
with (a) pyrimethamine for acute attacks and suppression,
and (b) trimethoprim in clinical attacks. They are sul-
phamethoxypyrazine (Kelfizina) with a serum half-life of
about 65 hours, and sulphormethoxine (Fanasil) with a
half-elimination time of 100 - 200 hours. Combined with
the folate reductase inhibitors, their antiplasmodial action
is rapid enough for use in the acute phase.
The Stevens-Johnson syndrome has been described, as
well as the emergence of resistant E. coli strains, when
these preparations have been used as suppressive agents.
Dapsone
Peak plasma levels are reached after 1 - 3 hours, and
the drug is detectable for 8 - 12 days. The kidneys are the
main pathway for excretion. The drug is also excreted in
milk. It is used in conjunction with pyrimethamine as a
suppressant, with no indication of resistance developing
after one year.
The most common untoward effect is haemolysis of a
varying degree. Doses of 100 mg or less in 'normal'
persons, and 50 mg or less in people with glucose-6-
phosphate dehydrogenase deficiency do not produce
haemolysis. Methaemoglobinaemia can occur. This drug
also has antimicrobial actions, albeit limited, and can
induce resistance in potentially pathogenic micro-
organisms.
Primaquin
- Plasma concentrations are maximal after 6 hours but
barely detectable after 24 hours due to the rapid biotrans-
formation to active quinoline-quinone derivatives. Plasma
levels do not correlate well with antimalarial activity.
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Quinacrine greatly enhances plasma concentration and
sojourn in the body. Doses are given daily for curative
purposes.
DRUG-RESISTANT STRAINS
Resistance may be acquired, or a strain may be naturally
insensitive, or relatively so, to a particular agent. Acquired
resistance may be the result of 'overgrowth' of the
naturally occurring resistant mutants, or the resistance can
be induced by inadequate blood levels of the therapeutic
agents.
A high degree of resistance can be induced against
chloroguanide and pyrimethamine, less easily so against
the 4- and 8-arninoquinolines and acridine derivatives.
Quinine is usually helpful against these multiresistant
strains, but should resistance to this alkaloid develop, re-
course is taken to the use of combinations, e.g. pyrime-
thamine with either a sulphonamide or dapsone, or trime-
thoprim with a sulphonamide.
PREVENTING OR LIMITING RESISTANCE
The use of a combination of drugs prevents or limits re-
sistance. The combination must be chosen so that the
half-lives of the components are similar (to ensure a con-
tinuous combined effect), e.g. chloroquine and pyrime-
thamine or the latter with either a long-acting sulphona-
mide or dapsone. One particular combination should be
employed until proof of the emergence of a resistant strain
is evident. Only then should the reserve combination be
administered. Likewise, combination drugs should be held
in reserve for treatment of the acute attack, until evidence
exists that strains in that area are resistant to the con-
ventional drugs (4-aminoquinolines).
Intermittent and inadequate chemosuppression of non-
immune and partially immune populations, who are con-
stantly being reinfected from indigenous reservoirs of
parasites, greatly favours the emergence and spread of
drug-resistant strains of malaria. Immune populations
should not be given chemosuppressives unless dosage
regimens are adequate and strictly adhered to.
In this context two factors must be stressed, i.e. the
unreliability of patients in taking medication, and factors
affecting bio-availability of the drug in question. The
adequacy of the treatment regimen can in many cases be
assessed by determination of plasma levels of the drug,
and reliability of ingestion of the drug by a qualitative
urine test.
Many so-called drug-resistance cases may be the result
of inadequate drug levels at the site of action.
Malaria Control •In the Northern Transvaal
SUMMARY
C. F. HANSFORD
IMMUNE STATUS IN RELATION TO STABLE
AND UNSTABLE MALARIA
Malaria epidemiology relating to control operations is
briefly reviewed. Control methods are discussed and
reference made to the staging of control programmes.
Details are given of current control operations in the
northern Transvaal, with particular reference to aspects of
importance to medical practitioners.
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An attempt is made to give a brief background of malaria
epidemiology as it affects control operations in the Trans-
vaal followed by an outline of control operations and
aspects which may affect medical practitioners and the
public.
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In this country P. jalciparum is responsible for over 95%·
of malaria infections and remarks are confined principally
to this type of malaria. Malaria may be classified as
stable or unstable. Stable malaria is present where tempera-
tures are high and vector mosquitoes are common and
have a moderate to high longevity. Malaria transmission
is regular and the vast majority of the population becomes
infected and reinfected from an early age, thus developing
a strong immunity. In these areas of high malaria trans-
mission (holo-endemic) spleen rates are often over 75%
in the 2 - lO-year age group, falling to lower levels in
adults. Infant mortality is high, but adults are relatively
free from clinical malaria in spite of a considerable
proportion showing low parasitaemia on blood examination.
Malaria is unstable where either climatic conditions are
subject to marked seasonal variations or the vector is
short-lived and less efficient. There are marked seasonal
and annual fluctuations in the incidence of malaria,
